Skip to content
2000
Volume 8, Issue 1
  • ISSN: 2405-4615
  • E-ISSN: 2405-4623

Abstract

Background: Treatment used for cancer is generally associated with serious side effects. New solutions for cancer therapy can overcome the shortcomings and problems of conventional therapies by designing drug delivery nanosystems. Methods: In this study, magnetic FeO@AU@albumin core-shell-shell (CSS) nanoparticles were synthesized and characterized by various analyses, such as transmission electron microscopy (TEM), X-ray diffraction (XRD), and vibrating sample magnetization (VSM). Podophyllotoxin (PPT) was then loaded on magnetic nanoparticles as an anti-cancer drug and its effect on HT-29 and MCF-7 cell lines was evaluated using an MTT assay. Results: The crystallinity of synthesized FeO magnetic nanoparticles was confirmed by XRD analysis. Next, a layer of gold was coated with the FeO MNPs. The UV-Vis analysis of core-shell nanoparticles (iron oxide/gold) confirmed the successful synthesis of these nanoparticles. The surface of the core-shell nanoparticles was then coated with albumin to load the drug. TEM image confirmed the existence of albumin nanoparticles loaded with core-shell magnetic nanoparticles. VSM analysis revealed that iron oxide, FeO@AU, and FeO@AU@albumin nanoparticles have the highest magnetic properties, respectively. After the synthesis of PPT loaded onto MNP, the loading efficiency was found to be 50%. The IC values of PPT alone and loaded onto nanoparticles on MCF-7 cells after 24 hours were 3085.75 and 1868.09 nM, respectively, which were significantly toxic (P-value ≤ 0.05) but not significant after 48 hours. The PPT loaded on nanoparticles was found to be significantly more toxic to HT-29 cells after 24 and 48 h than PPT alone (P-value ≤ 0.05). Conclusion: The anticancer drug of PPT-loaded MNPs has significant advantages over PPT alone due to its improved properties with appropriate cytotoxic activity. Thus, the PPT-loaded MNPs may be considered effective anti-cancer agents for further research on drug development.

Loading

Article metrics loading...

/content/journals/cnm/10.2174/2405461507666220204100719
2023-04-01
2025-03-11
Loading full text...

Full text loading...

/content/journals/cnm/10.2174/2405461507666220204100719
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test